ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Moderate Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $107.3333.

Several research firms recently weighed in on ANIP. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Guggenheim increased their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th.

ANI Pharmaceuticals Stock Performance

ANIP opened at $74.14 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 22.07 and a beta of 0.52. ANI Pharmaceuticals has a 52-week low of $56.71 and a 52-week high of $99.50. The firm’s fifty day simple moving average is $77.83 and its two-hundred day simple moving average is $84.11.

Insider Activity at ANI Pharmaceuticals

In other news, insider Christopher Mutz sold 3,162 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $71.64, for a total value of $226,525.68. Following the transaction, the insider directly owned 91,309 shares of the company’s stock, valued at approximately $6,541,376.76. This trade represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $72.62, for a total transaction of $36,310.00. Following the transaction, the vice president owned 79,390 shares in the company, valued at $5,765,301.80. The trade was a 0.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,860 shares of company stock worth $2,114,771 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ANIP. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. increased its holdings in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the last quarter. Newbridge Financial Services Group Inc. lifted its position in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after buying an additional 400 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the fourth quarter worth approximately $48,000. Finally, State of Wyoming acquired a new position in ANI Pharmaceuticals during the second quarter worth $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.